Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02064673 · ClinicalTrials.gov registry record · Phase 3
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
A Phase 3 study of Prostate Cancer, sponsored by yair lotan.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 608
- Enrollment target
- 1
- Study location
NCT02064673: Recruiting Phase 3 study of Prostate Cancer, sponsored by yair lotan.
NCT02064673 is a Phase 3 study of Prostate Cancer that is actively recruiting participants, run by yair lotan. The registered enrollment target is 608 participants, roughly in line with the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02064673, a Phase 3 study of Prostate Cancer, is actively recruiting participants, sponsored by yair lotan.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 608 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective study to determine if the adjuvant use of Curcumin improves recurrence-free survival.
Primary Outcome
Recurrence free survival defined as a total serum prostate specific antigen of \<0.2ng/ml.
Conditions Studied
Interventions
- DRUG placebo
- DRUG Curcumin
Study Locations (1)
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 608 participants |
| Start Date | 2014-05 |
| Est. Completion | 2028-12 |
| Phase | Phase 3 |
What NCT02064673 shows while recruiting
NCT02064673 is an interventional study that assigns participants to a tested intervention. The registered 608 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT02064673 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02064673 about?
NCT02064673 is a clinical study titled "Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy". This is a prospective study to determine if the adjuvant use of Curcumin improves recurrence-free survival.
What is the current status of trial NCT02064673?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 608 participants. The study started on 2014-05. Estimated completion is 2028-12.
What conditions does trial NCT02064673 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT02064673?
The interventions under investigation include: placebo (DRUG), Curcumin (DRUG).
Who is sponsoring clinical trial NCT02064673?
This trial is sponsored by yair lotan, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02064673 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02064673's enrollment target sits among peer trials
608 94th of 735 higher than 642 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06091202 · 608 participants · Phase 3
Tele-Collaborative Outreach to Rural Patients With Chronic Pain
- NCT06098144 · 608 participants · Phase 4
Smoking Cessation Program in the Construction Sector
- NCT00823654 · 609 participants
Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations
- NCT03536312 · 610 participants · NA
Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia